Scope Fluidics obtains patent protection for the PCR|ONE technology in China

Curiosity Diagnostics, owned by Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects, obtained a Chinese patent which protects the key technology of the PCR|ONE system. This is another foreign patent obtained by the Company, which also means a monopoly in China on the commercial use of the unique module which is part of the PCR|ONE analyzer.

The China National Intellectual Property Administration granted to the company a patent which protects the technology applied in the PCR|ONE system. With this technology, the PCR|ONE analyzer is capable of performing an ultra-fast polymerase chain reaction (PCR) on multiple samples simultaneously. The Chinese patent is the third one held by Curiosity Diagnostics. The company has previously obtained patents for its invention in the United States and Europe.

– We have managed to ensure protection for the PCR|ONE system technology on three continents. The system addresses the global need for rapid, informative molecular diagnostics, and it is important confirmation for us that our solutions are truly innovative. The Chinese patent is also a significant part of the discussions we have been holding on the commercialization of the device – says Prof. Piotr Garstecki, co-founder, key shareholder and CEO of Scope Fluidics.

The PCR|ONE system conducts fully automatic analysis of genetic material of bacterial and viral pathogens. The instrument is unrivalled in terms of analysis rapidity and comprehensiveness – it can identify up to several dozen pathogens within several minutes of sampling. The company will offer several panels targeted at the most serious threats to human health. The first one, on which work is almost completed, is a panel detecting methicillin-resistant strains of Staphylococcus aureus (MRSA), which are a frequent cause of hospital-acquired infections demonstrating high antibiotic-resistance. In March, Scope Fluidics also announced the start of works on expanding the portfolio of PCR|ONE tests. The company decided to extend the work on the panel for the diagnosis of viral respiratory tract infections to include the development of an ultra-fast test for the detection of SARS-CoV-2 virus causing Covid-19. The development of an additional panel is expected to increase the business attractiveness of the PCR|ONE system for future buyers.